124 related articles for article (PubMed ID: 12076452)
1. Second-line chemotherapy for non-small cell lung cancer.
Bonfill X; Serra C; Sacristán M; Nogué M; Losa F; Montesinos J
Cochrane Database Syst Rev; 2002; (2):CD002804. PubMed ID: 12076452
[TBL] [Abstract][Full Text] [Related]
2. Second-line chemotherapy for non-small cell lung cancer.
Bonfill X; Serra C; Sacristán M; Nogué M; Losa F; Montesinos J
Cochrane Database Syst Rev; 2001; 2002(4):CD002804. PubMed ID: 11687161
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy versus best supportive care for extensive small cell lung cancer.
Pelayo Alvarez M; Westeel V; Cortés-Jofré M; Bonfill Cosp X
Cochrane Database Syst Rev; 2013 Nov; (11):CD001990. PubMed ID: 24282143
[TBL] [Abstract][Full Text] [Related]
4. Docetaxel for previously treated non-small-cell lung cancer.
Fossella FV
Oncology (Williston Park); 2002 Jun; 16(6 Suppl 6):45-51. PubMed ID: 12108897
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy versus best supportive care for extensive small cell lung cancer.
Agra Y; Pelayo M; Sacristan M; Sacristán A; Serra C; Bonfill X
Cochrane Database Syst Rev; 2003; (4):CD001990. PubMed ID: 14583943
[TBL] [Abstract][Full Text] [Related]
6. Review of two phase III randomized trials of single-agent docetaxel in previously treated advanced non--small cell lung cancer.
Lynch TJ
Semin Oncol; 2001 Jun; 28(3 Suppl 9):5-9. PubMed ID: 11444253
[TBL] [Abstract][Full Text] [Related]
7. Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation.
Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Hockenhull J; Proudlove C; Dundar Y; Richardson M; Dickson R; Mullard A; Marshall E
Health Technol Assess; 2015 Jun; 19(47):1-134. PubMed ID: 26134145
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy versus best supportive care for extensive small cell lung cancer.
Pelayo Alvarez M; Gallego Rubio O; Bonfill Cosp X; Agra Varela Y
Cochrane Database Syst Rev; 2009 Oct; (4):CD001990. PubMed ID: 19821287
[TBL] [Abstract][Full Text] [Related]
9. Second-line chemotherapy for non-small-cell lung cancer.
Fossella FV
Curr Oncol Rep; 2000 Jan; 2(1):96-101. PubMed ID: 11122830
[TBL] [Abstract][Full Text] [Related]
10. Docetaxel (Taxotere) shows survival and quality-of-life benefits in the second-line treatment of non-small cell lung cancer: a review of two phase III trials.
Shepherd FA; Fossella FV; Lynch T; Armand JP; Rigas JR; Kris MG
Semin Oncol; 2001 Feb; 28(1 Suppl 2):4-9. PubMed ID: 11284623
[TBL] [Abstract][Full Text] [Related]
11. Paclitaxel: a pharmacoeconomic review of its use in non-small cell lung cancer.
Plosker GL; Hurst M
Pharmacoeconomics; 2001; 19(11):1111-34. PubMed ID: 11735678
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of docetaxel and ifosfamide combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy with or without paclitaxel.
Chen YM; Shih JF; Lee CS; Chen MC; Lin WC; Tsai CM; Perng RP
Lung Cancer; 2003 Feb; 39(2):209-14. PubMed ID: 12581575
[TBL] [Abstract][Full Text] [Related]
13. Taxanes as first-line therapy for advanced non-small cell lung cancer: a systematic review and practice guideline.
Chu Q; Vincent M; Logan D; Mackay JA; Evans WK;
Lung Cancer; 2005 Dec; 50(3):355-74. PubMed ID: 16139391
[TBL] [Abstract][Full Text] [Related]
14. Docetaxel: a review of its use in non-small cell lung cancer.
Comer AM; Goa KL
Drugs Aging; 2000 Jul; 17(1):53-80. PubMed ID: 10933515
[TBL] [Abstract][Full Text] [Related]
15. Docetaxel for locally advanced or metastatic non-small-cell lung cancer. Current data and future directions as front-line therapy.
Khuri FR
Oncology (Williston Park); 2002 Jun; 16(6 Suppl 6):53-62. PubMed ID: 12108898
[TBL] [Abstract][Full Text] [Related]
16. Docetaxel (Taxotere) in the treatment of non-small cell lung cancer (NSCLC)--is there a role for a new chemotherapy programme?
Armand JP
Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():223-30. PubMed ID: 10895158
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy for advanced non-small cell lung cancer: standards.
Manegold C
Lung Cancer; 2001 Dec; 34 Suppl 2():S165-70. PubMed ID: 11720760
[TBL] [Abstract][Full Text] [Related]
18. Docetaxel as second-line chemotherapy for non-small-cell lung cancer.
Roila F; Del Favero A; Ballatori E
J Clin Oncol; 2000 Nov; 18(21):3738-9. PubMed ID: 11054450
[No Abstract] [Full Text] [Related]
19. Chemotherapy for non-small cell lung cancer.
Non-small Cell Lung Cancer Collaborative Group
Cochrane Database Syst Rev; 2000; 2000(2):CD002139. PubMed ID: 10796867
[TBL] [Abstract][Full Text] [Related]
20. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Fossella FV; DeVore R; Kerr RN; Crawford J; Natale RR; Dunphy F; Kalman L; Miller V; Lee JS; Moore M; Gandara D; Karp D; Vokes E; Kris M; Kim Y; Gamza F; Hammershaimb L
J Clin Oncol; 2000 Jun; 18(12):2354-62. PubMed ID: 10856094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
